I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $357.9M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| ||||
ActivBiotics |
Lexington, Mass. |
8/4 |
$26.4 |
ActivBiotics raised $26.4M in a Series B round led by MDS Capital Corp.; other investors were BioVentures Investors, F. Hoffmann-La Roche Ltd., China Development Industrial Bank, New England Partners, HealthCare Ventures LLC and Delphi Ventures LP |
|
||||
Biolex Inc. |
Pittsboro, N.C. |
8/19 |
$24 |
Biolex raised $24M in a round led by Quaker BioVentures and Intersouth Partners; other investors were Johnson & Johnson Development Corp., Mitsui & Co. Venture Partners, The Dow Chemical Co., Dogwood Equity, Trelys Venture Partners, The Wakefield Group, Kitty Hawk Capital, Franklin Street Partners, Tall Oaks Capital and Academy Centennial Fund |
|
||||
BioStratum Inc. |
Research Triangle Park, N.C. |
8/21 |
$9.5 |
BioStratum raised $9.5M in a bridge financing; investors were HealthCap, BankInvest, Liftaeknisjodurinn hf and Equity Resources Group Inc. |
|
||||
CancerVax |
Carlsbad, Calif. |
8/14 |
$41 |
CancerVax raised $41M in a Series C round of financing from a group of undisclosed new and existing investors |
Chlorogen Inc. |
St. Louis |
8/6 |
ND |
Chlorogen secured an undisclosed amount of venture funding from investors Burrill & Co., Redmont Venture Partners, Prolog Ventures and Harris & Harris Group Inc. |
|
||||
Clearant Inc. |
Los Angeles |
8/13 |
$18 |
Clearant raised $18M in a Series B financing round, mostly from new institutional investors |
Coley Pharmaceutical Group Inc. |
Wellesley, Mass. |
8/25 |
$35 |
Coley raised $35M in a private financing; investors were Thomas, McNerney & Partners; Venrock Associates; Techno Venture Management; and Global Life Science Ventures |
|
||||
GeneXP Biosciences Inc. |
Woburn, Mass. |
8/11 |
$2 |
GeneXP raised $2M in a financing from Ingalls & Snyder LLC |
|
||||
GTx Inc. |
Memphis, Tenn. |
8/20 |
$20 |
GTx raised $20M in a financing with investors J.R. Hyde III, Oracle Partners LP and Memphis Biomed Ventures I LP |
Kemia Inc. |
San Diego |
8/18 |
$19 |
Kemia raised a total of more than $19M in a Series A financing; investors were Alta Partners, Forward Ventures and Texas Pacific Group, as well as Novartis BioVentures |
|
||||
Metabolex Inc. |
Hayward, Calif. |
8/27 |
$27 |
Metabolex raised $27M in a financing co-led by Bay City Capital, BTF and CDP Capital Technology; other investors were Charter Ventures Capital and KBC; CIBC World Markets Corp. acted as agent for the financing |
|
||||
Myogen Inc. |
Denver |
8/28 |
$40 |
Myogen raised $40M in a Series D financing with a group of institutional investors led by New Enterprise Associates; other investors were J.P. Morgan, InterWest Partners, Sequel Venture Partners Ltd., Perseus-Soros Biopharmaceutical Fund LP,CMEA Ventures and Pacific Rim Ventures |
|
||||
NuGEN |
San Carlos, Calif. |
8/19 |
$7.5 |
NuGEN raised $7.5M after completing a Series C round of financing led by William Rutter, George Rathmann and James Wilson; other investors were Sutter Hill Ventures, Radius Venture Partners, The Band of Angels Fund and MedCapital Ventures |
|
||||
Renovis Inc. |
South San Francisco |
8/11 |
$45 |
Renovis raised $45M through a Series E round led by Easton Hunt Capital Partners; other investors were HealthCap, MDS Capital, Invus Group, CDIB BioScience Ventures, Alta Partners, Venrock Associates, Flagship Ventures, Skyline Ventures and HBM BioVentures, among others |
|
||||
Rinat Neuroscience Corp. |
Palo Alto, Calif. |
8/20 |
$40 |
Rinat raised $40M in a Series B round led by MPM Capital; other investors were Schroder Life Sciences, Prospect Venture Partners, Technology Partners and Essex Woodlands Health Ventures |
Targeted Molecules Corp. Partnership, Inglewood Ventures LP, Linkagene |
San Diego |
8/20 |
$3.5 |
Targeted Molecules raised $3.5M in a private round; investors were Neuro Discovery Ltd. LP and Trian Equities Ltd. |
|
||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $19.8M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
| ||||
Exact |
Laboratory Corp. of America Holdings (NYSE:LH) |
$15 |
Milestone payment |
Exact Sciences achieved a $15M milestone due to the national commercial availability of PreGen-Plus, a DNA-based stool assay for the early detection of colorectal cancer (8/13) |
|
||||
Genome Therapeutics Corp. (GENE) |
Amgen Inc. (AMGN) |
ND |
Milestone payment |
Genome Therapeutics received a payment from Amgen for the completion of a milestone under their agreement to use genetic information to discover and commercialize therapeutics for bone diseases, including osteoporosis (8/11) |
|
||||
Targeted Genetics Corp. (TGEN) |
Biogen Inc. (BGEN) |
$4.8 |
Equity investment |
Targeted received $4.8M through Biogen's purchase of 2.5M common shares (8/18) |
|
||||
TransForm Pharmaceuticals Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
ND |
Milestone payment |
TransForm said it would receive an undisclosed milestone payment after making the first crystalline form of a compound belonging to Roche (8/5) |
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
ND = Not disclosed. | ||||
NYSE = New York Stock Exchange. |